Plain-English translation of NCT05984342 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing whether combining standard chemotherapy with a new immunotherapy drug called works better after surgery for esophageal cancer that has spread to the lymph nodes. The medication is designed to help your immune system fight any remaining cancer cells after your surgery. Researchers want to see if this combination treatment can help you stay cancer-free longer and live longer overall.
Surgery is the main treatment for your type of esophageal cancer, but many patients still have their cancer return after surgery. While similar immunotherapy treatments have helped patients in other studies, doctors don't yet know the best way to treat your specific type of cancer after surgery, so this trial will test whether adding this medication to chemotherapy makes a real difference.
You likely qualify if…
You likely don't qualify if…
If you join this trial, you will receive the medication combined with standard chemotherapy after your surgery. You will have regular visits to receive your treatment, blood tests to monitor your health, and follow-up appointments to check for side effects and whether your cancer has returned. The study will track your progress over time to see how well this combined treatment works for you and to make sure it is safe.
AI-generated summary from trial data · Jun 13, 2026 · Not medical advice
China